Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2017

01-10-2017 | Research Article

Perceptions and behaviors of patients and pharmacists towards generic drug substitution in Lebanon

Authors: Shadi Saleh, Clara Abou Samra, Stewart Jleilaty, Joanne Constantin, Nour El Arnaout, Hani Dimassi, Dania Al-Bittar

Published in: International Journal of Clinical Pharmacy | Issue 5/2017

Login to get access

Abstract

Background Patients, physicians and pharmacists are key stakeholders in the implementation of generic substitution policies. Objectives To explore Lebanese patients’ perceptions and experience, and pharmacists’ dispensing patterns towards the newly enacted unified health prescription policy promoting generic substitution. Setting Pharmacies in Beirut, the capital of Lebanon. Methods A cross-sectional design employing self-administered questionnaires to survey a total of 128 patients and 25 pharmacists. Chi square test and multiple logistic regression were performed. Main outcome Perceptions and behaviors of patients and pharmacists towards the unified health prescription and generic substitution. Results Fourty-eight percent of the patients knew the definition of generic drugs, among which 59.0% perceived that generic drugs have the same effectiveness as their branded alternatives and 59.0% perceiving that generic drugs could reduce Lebanon’s medical bill as well. Sixty-one percent of the patients were aware of the unified health prescription. Only 13.6% of the pharmacists suggested to patients to replace prescribed brand drug by a generic when their prescriptions were not marked with non-substitution. Conclusions Progress has been made with regards to enhancing generic substitution in the Lebanese healthcare field. However, it remains important to educate patients about generic medicines and plan context-specific schemes that promote prescribing and dispensing of generic drugs among physicians and pharmacists.
Literature
2.
go back to reference Andersson K, Bergström G, Petzold MG, Carlsten A. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy. 2007;81(2):376–84.CrossRefPubMed Andersson K, Bergström G, Petzold MG, Carlsten A. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy. 2007;81(2):376–84.CrossRefPubMed
3.
go back to reference Gerdtham U-G, Lundin D. Why did drug spending increase during the 1990s? Pharmacoeconomics. 2004;22(1):29–42.CrossRefPubMed Gerdtham U-G, Lundin D. Why did drug spending increase during the 1990s? Pharmacoeconomics. 2004;22(1):29–42.CrossRefPubMed
4.
go back to reference Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.CrossRefPubMed Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.CrossRefPubMed
5.
go back to reference Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S. Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99(1):60–5.CrossRefPubMed Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S. Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99(1):60–5.CrossRefPubMed
6.
go back to reference Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.CrossRefPubMed Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.CrossRefPubMed
7.
go back to reference Fabiano V, Mameli C, Cattaneo D, Delle Fave A, Preziosa A, Mele G, et al. Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. Health Policy. 2012;104(3):247–52.CrossRefPubMed Fabiano V, Mameli C, Cattaneo D, Delle Fave A, Preziosa A, Mele G, et al. Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. Health Policy. 2012;104(3):247–52.CrossRefPubMed
8.
go back to reference Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38(4):1051–64.CrossRefPubMedPubMedCentral Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38(4):1051–64.CrossRefPubMedPubMedCentral
9.
go back to reference Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13(4):207–14.CrossRefPubMed Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13(4):207–14.CrossRefPubMed
10.
go back to reference Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–62.CrossRefPubMed Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–62.CrossRefPubMed
11.
go back to reference McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf. 2001;10(4):295–300.CrossRefPubMed McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf. 2001;10(4):295–300.CrossRefPubMed
12.
go back to reference Hellerstein JK. The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ. 1998;29(1):108–36.CrossRefPubMed Hellerstein JK. The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ. 1998;29(1):108–36.CrossRefPubMed
13.
go back to reference Karim SA, Pillai G, Ziqubu-Page T, Cassimjee M, Morar M. Potential savings from generic prescribing and generic substitution in South Africa. Health policy Plan. 1996;11(2):198–202.CrossRefPubMed Karim SA, Pillai G, Ziqubu-Page T, Cassimjee M, Morar M. Potential savings from generic prescribing and generic substitution in South Africa. Health policy Plan. 1996;11(2):198–202.CrossRefPubMed
14.
go back to reference King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croatian Med J. 2002;43(4):462–9. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croatian Med J. 2002;43(4):462–9.
15.
go back to reference Lofgren H. Generic drugs: international trends and policy developments in Australia. Aust Health Rev. 2004;27(1):39–48.CrossRefPubMed Lofgren H. Generic drugs: international trends and policy developments in Australia. Aust Health Rev. 2004;27(1):39–48.CrossRefPubMed
16.
go back to reference Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28(5):284–9.CrossRefPubMed Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28(5):284–9.CrossRefPubMed
19.
go back to reference Mahdi H. Unified prescription form: NSSF in the service of drug monopolies. Al Akhbar. 2015 Tuesday, 10 Feb 2015. Mahdi H. Unified prescription form: NSSF in the service of drug monopolies. Al Akhbar. 2015 Tuesday, 10 Feb 2015.
20.
go back to reference Olsson E, Kälvemark Sporrong S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20(6):377–83.CrossRefPubMed Olsson E, Kälvemark Sporrong S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20(6):377–83.CrossRefPubMed
21.
go back to reference Yousefi N, Mehralian G, Peiravian F, NourMohammadi S. Consumers’ perception of generic substitution in Iran. Int J Clin Pharm. 2015;37(3):497–503.CrossRefPubMed Yousefi N, Mehralian G, Peiravian F, NourMohammadi S. Consumers’ perception of generic substitution in Iran. Int J Clin Pharm. 2015;37(3):497–503.CrossRefPubMed
22.
go back to reference Figueiras MJ, Marcelino D, Cortes MA. People’s views on the level of agreement of generic medicines for different illnesses. Pharm World Sci. 2008;30(5):590–4.CrossRefPubMed Figueiras MJ, Marcelino D, Cortes MA. People’s views on the level of agreement of generic medicines for different illnesses. Pharm World Sci. 2008;30(5):590–4.CrossRefPubMed
23.
go back to reference Banahan BF, Kolassa E. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157(18):2080–8.CrossRefPubMed Banahan BF, Kolassa E. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157(18):2080–8.CrossRefPubMed
24.
go back to reference Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (1996). 2000;40(3):378–83.CrossRef Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (1996). 2000;40(3):378–83.CrossRef
25.
go back to reference Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers’ views on generic medicines: a review of the literature. Int J Pharm Pract. 2009;17(2):79–88.PubMed Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers’ views on generic medicines: a review of the literature. Int J Pharm Pract. 2009;17(2):79–88.PubMed
26.
go back to reference Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J, Brookhart AM, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009;47(3):319.CrossRefPubMedPubMedCentral Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J, Brookhart AM, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009;47(3):319.CrossRefPubMedPubMedCentral
27.
go back to reference Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci. 1999;21(6):260–5.CrossRefPubMed Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci. 1999;21(6):260–5.CrossRefPubMed
28.
go back to reference Hamadeh GN, Dickerson LM, Saab BR, Major SC. Common prescriptions in ambulatory care in Lebanon. Ann Pharmacother. 2001;35(5):636–40.CrossRefPubMed Hamadeh GN, Dickerson LM, Saab BR, Major SC. Common prescriptions in ambulatory care in Lebanon. Ann Pharmacother. 2001;35(5):636–40.CrossRefPubMed
29.
go back to reference Sharif S, Al-Shaqra M, Hajjar H, Shamout A, Wess L. Patterns of drug prescribing in a hospital in Dubai, United Arab Emirates. Libyan J Med. 2008;3(1):10–2.CrossRefPubMedPubMedCentral Sharif S, Al-Shaqra M, Hajjar H, Shamout A, Wess L. Patterns of drug prescribing in a hospital in Dubai, United Arab Emirates. Libyan J Med. 2008;3(1):10–2.CrossRefPubMedPubMedCentral
31.
go back to reference Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy. 2011;99(2):139–48.CrossRefPubMed Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy. 2011;99(2):139–48.CrossRefPubMed
32.
go back to reference Grover P, Stewart J, Hogg M, Short L, Seo HG, Rew A. Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand. Res Soc Adm Pharm. 2011;7(3):294–305.CrossRef Grover P, Stewart J, Hogg M, Short L, Seo HG, Rew A. Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand. Res Soc Adm Pharm. 2011;7(3):294–305.CrossRef
33.
go back to reference Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12):e008915.CrossRefPubMedPubMedCentral Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12):e008915.CrossRefPubMedPubMedCentral
Metadata
Title
Perceptions and behaviors of patients and pharmacists towards generic drug substitution in Lebanon
Authors
Shadi Saleh
Clara Abou Samra
Stewart Jleilaty
Joanne Constantin
Nour El Arnaout
Hani Dimassi
Dania Al-Bittar
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2017
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0509-4

Other articles of this Issue 5/2017

International Journal of Clinical Pharmacy 5/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.